

University of Groningen

Optimizing diagnostics for patient tailored treatment choices in patients with metastatic renal cell carcinoma and breast cancer

van Es, Suzanne

DOI:
[10.33612/diss.133333586](https://doi.org/10.33612/diss.133333586)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2020

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):
van Es, S. (2020). *Optimizing diagnostics for patient tailored treatment choices in patients with metastatic renal cell carcinoma and breast cancer*. University of Groningen. <https://doi.org/10.33612/diss.133333586>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

**Optimizing diagnostics for patient tailored
treatment choices in patients with metastatic renal
cell carcinoma and breast cancer**

Suzanne Charlotte van Es

Optimizing diagnostics for patient tailored treatment choices in patients with metastatic renal cell carcinoma and breast cancer

Proefschrift

ter verkrijging van de graad van doctor aan de
Rijksuniversiteit Groningen
op gezag van de
rector magnificus prof. dr. C. Wijmenga
en volgens besluit van het College voor Promoties.

De openbare verdediging zal plaatsvinden op

dinsdag 6 oktober 2020 om 11.00 uur

door

Suzanne Charlotte van Es

geboren op 29 oktober 1990
te Alphen aan den Rijn

Cover: Ilse Modder | www.ilsemodder.nl
Lay-out: Ilse Modder | www.ilsemodder.nl
Printing: Gildeprint B.V. | www.gildeprint.nl



The printing of this thesis was financially supported by the Stichting Werkgroep Interne Oncologie, Universitair Medisch Centrum Groningen; Graduate School of Medical Sciences, Rijksuniversiteit Groningen; Uitgeverij Jaap; Alrijne Zorggroep; Erbe Nederland B.V. and NoordNegentig.

Copyright © Suzanne Charlotte van Es, 2020

All rights reserved. No part of this thesis may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronically, mechanically, by photocopy, by recording, or otherwise, without prior written permission of the author.

Promotores

Prof. dr. E.G.E. de Vries

Dr. C.P. Schroder

Copromotor

Dr. S.F. Oosting

Beoordelingscommissie

Prof. dr. H.M.W. Verheul

Prof. dr. R.A.J.O. Dierckx

Prof. dr. A.K.L. Reyners

Paranimfen

Eline van Es

Kirsten Moek

Contents

Chapter 1	General introduction and outline of the thesis	9
Chapter 2	Lesion detection by ⁸⁹ Zr-girentuximab and ¹⁸ F-FDG PET/CT in patients with newly diagnosed metastatic renal cell carcinoma <i>Eur J Nucl Med Mol Imaging. 2019;46: 1931-1939.</i>	19
Chapter 3	⁸⁹ Zr-bevacizumab PET visualizes heterogeneous tracer accumulation in tumor lesions of renal cell carcinoma patients and differential effects of antiangiogenic treatment <i>J Nucl Med. 2015;56: 63-69.</i>	39
Chapter 4	⁸⁹ Zr-bevacizumab PET: Potential early indicator of everolimus efficacy in patients with metastatic renal cell carcinoma <i>J Nucl Med. 2017;58: 905-910.</i>	61
Chapter 5	Balancing treatment efficacy, toxicity and complication risk in elderly patients with metastatic renal cell carcinoma <i>Cancer Treat Rev. 2016;46: 63-72.</i>	79
Chapter 6	Translation of new molecular imaging approaches to the clinical setting: Bridging the gap to implementation <i>J Nucl Med. 2016;57 Supplemental 1: 96S-104S.</i>	107
Chapter 7	Assessment of bone lesions with ¹⁸ F-FDG PET compared to ^{99m} Tc-technetium bone scintigraphy leads to clinically relevant differences in metastatic breast cancer management <i>Accepted for publication by J Nucl Med. on May 7, 2020.</i>	129
Chapter 8	Decalcification of breast cancer bone metastases with EDTA does not affect ER, PR and HER2 results <i>Am J Surg Pathol. 2019;43: 1355-1360.</i>	151
Chapter 9	Summary	167
Chapter 10	General discussion and future perspectives	175
Chapter 11	Nederlandse samenvatting	183
Chapter 12	Dankwoord	191